Renovacor, Inc. (RCOR)
| Market Cap | 29.25M |
| Revenue (ttm) | n/a |
| Net Income (ttm) | -6.13M |
| Shares Out | 17.27M |
| EPS (ttm) | -0.47 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 1,852 |
| Open | 1.74 |
| Previous Close | 1.65 |
| Day's Range | 1.69 - 1.74 |
| 52-Week Range | 1.34 - 10.74 |
| Beta | 0.12 |
| Analysts | Buy |
| Price Target | 18.36 (+983.8%) |
| Earnings Date | Aug 11, 2022 |
About RCOR
Renovacor, Inc., a biotechnology company, focuses on delivering various precision therapies to enhance the lives of patients and families battling genetically-driven cardiovascular and mechanistically-related diseases. It primarily focuses on the treatment of BCL2-associated athanogene 3 (BAG3) mutation-associated dilated cardiomyopathy (DCM). The company's lead product candidate is REN-001, a recombinant adeno-associated virus 9-based gene therapy designed to deliver a functional BAG3 gene to augment BAG3 protein levels in cardiomyocytes, and ... [Read more...]
Financial Performance
Financial StatementsAnalyst Forecast
According to 9 analysts, the average rating for RCOR stock is "Buy." The 12-month stock price forecast is 18.36, which is an increase of 983.83% from the latest price.
News
Renovacor Reports Second Quarter 2022 Financial Results and Provides Corporate Update
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Renovacor, Inc. (NYSE: RCOR), a biotechnology company focused on delivering innovative precision therapies to improve the lives of patients and families battling genet...
Renovacor Announces Pipeline Expansion with New Research Program for Multiple Genetic Segments of Arrhythmogenic Card...
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Renovacor, Inc. (NYSE: RCOR), a biotechnology company focused on delivering innovative precision therapies to improve the lives of patients and families battling genet...
Renovacor Announces Data from Pilot Pig Study Showing Successful Cardiac Transduction with REN-001 Delivered Via Low-...
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Renovacor, Inc. (NYSE: RCOR), a biotechnology company focused on delivering innovative precision therapies to improve the lives of patients and families battling genet...
Renovacor Reports First Quarter 2022 Financial Results and Provides Corporate Update
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Renovacor, Inc. (NYSE: RCOR), a biotechnology company focused on delivering innovative precision therapies to improve the lives of patients and families battling genet...
Renovacor Announces the Appointment of Fred Driscoll as Chief Financial Officer
PHILADELPHIA--(BUSINESS WIRE)--Renovacor, Inc. (NYSE: RCOR), a biotechnology company focused on delivering innovative precision therapies to improve the lives of patients and families battling genetical...
Renovacor Reports Fourth Quarter and Full Year 2021 Financial Results and Provides Corporate Update
PHILADELPHIA--(BUSINESS WIRE)--Renovacor, Inc. (NYSE: RCOR), a biotechnology company focused on delivering innovative precision therapies to improve the lives of patients and families battling genetical...
Renovacor to Present at the 42nd Annual Cowen Health Care Conference
PHILADELPHIA--(BUSINESS WIRE)--Renovacor, Inc. (NYSE: RCOR), a biotechnology company focused on delivering innovative precision therapies to improve the lives of patients and families battling genetical...
Renovacor Announces Partnerships with the Dilated Cardiomyopathy Foundation, the Heart Failure Society of America and...
PHILADELPHIA--(BUSINESS WIRE)--Renovacor, Inc. (NYSE: RCOR), a biotechnology company focused on delivering innovative precision therapies to improve the lives of patients and families battling genetical...
Renovacor to Participate in a Panel Presentation at the 11th Annual LifeSci Partners Corporate Access Event
PHILADELPHIA--(BUSINESS WIRE)--Renovacor, Inc. (NYSE: RCOR), a biotechnology company focused on delivering innovative precision therapies to improve the lives of patients and families battling genetical...
Renovacor Announces Third Quarter 2021 Financial Results and Provides Corporate Update
PHILADELPHIA--(BUSINESS WIRE)--Renovacor, Inc. (NYSE: RCOR), a biotechnology company focused on delivering innovative precision therapies to improve the lives of patients and families battling genetical...
Renovacor, Inc. Closes Its Business Combination with Chardan Healthcare Acquisition 2 Corp. and Will Begin Trading on...
PHILADELPHIA--(BUSINESS WIRE)--Renovacor, Inc. Closes its Business Combination with Chardan Healthcare Acquisition 2 Corp. and Will Begin Trading on the New York Stock Exchange.
Chardan Healthcare Acquisition 2 Corp. Announces Stockholder Approval Of Business Combination With Renovacor, Inc.
NEW YORK, Sept. 1, 2021 /PRNewswire/ -- Chardan Healthcare Acquisition 2 Corp. (NYSE: CHAQ) ("CHAQ"), a special purpose acquisition company sponsored by Chardan Capital Markets ("Chardan"), today announ...
Chardan Healthcare Acquisition 2 Corp. Announces Renovacor's Appointment of Matt Killeen, Ph.D., as Chief Scientific ...
NEW YORK, Aug. 25, 2021 /PRNewswire/ -- Renovacor, Inc. ("Renovacor"), an early–stage biotechnology company developing adeno-associated virus (AAV)–based gene therapies for devastating cardiovascular an...
Renovacor Announces the Appointment of Jiwen Zhang, Ph.D., as Senior Vice President, Regulatory Affairs and Quality A...
Dr. Zhang has over 20 years of experience in regulatory affairs, with over a decade specifically in the field of cell and gene therapy Dr. Zhang has over 20 years of experience in regulatory affairs, wi...
Renovacor Announces the Appointments of Joan Lau, Ph.D., and Gregory F.
Appointments to be effective upon closing of the previously announced merger between Renovacor and Chardan Healthcare Acquisition 2 Corp. Appointments to be effective upon closing of the previously anno...
SHAREHOLDER ALERT: Monteverde & Associates PC Announces an Investigation of Chardan Healthcare Acquisition 2 Corp. - ...
NEW YORK, March 27, 2021 /PRNewswire/ -- Juan Monteverde , founder and managing partner at Monteverde & Associates PC, a national securities firm rated Top 50 in the 2018 and 2019 ISS Securities Class A...
Renovacor, Inc. to Merge with Chardan Healthcare Acquisition 2 Corp.
PHILADELPHIA and NEW YORK, March 23, 2021 /PRNewswire/ -- Renovacor, Inc. ("Renovacor" or the "Company"), an early-stage biotechnology company developing AAV-based gene therapies for devastating cardiov...